Replies to post #732639 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

suit,

I doubt that anyone is interested in 2016 😶

We are interested in the combo trials that have reached PII, and we are interested in the combo data that we will see in 2025, and we are interested in the additional combo trials that haven’t commenced yet. Even after an initial approval and initial commercialization, combo studies will be ongoing and we will be looking forward to see how big the cell-based platform(s) might become. Commercialization leads to further clinical trials—pembrolizumab was initially commercialized a decade ago, and it has been in ongoing clinical trials ever since…

Checkpoint inhibitors are in clinical trials with TWO patent-fortified novel dendritic cell technologies owned by NWBO: The U.S. DoD awarded a peer-reviewed grant to fund the pembrolizumab combo research at Roswell Park which has reached PII, and the U.S. NIH awarded a continuing peer-reviewed grant to fund the pembrolizumab combo research at UCLA.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927

[dstock07734]

This webpage has the latest update. The collaboration trial was listed too. Did they make a mistake?

I am ready to make money from those betting against revolutionary science.

https://www.rlp-forschung.de/public/facilities/2807/research_projects

[exwannabe]

The colon combo trial actually was listed as an upcoming trial by the German university but never started.

There have been several such trials that have been listed but just vanished w/o a trace.

The Opdivo combo trial (that actually was to use DCVax-L)
The infamous DCvax-prostate
The Direct brain mets trial
The -L P2 in ovarian